Axiscades misses its own growth targets for the second consecutive year
Management promised 45% EBITDA growth, but delivered 24.6% as revenue recognition slipped and a non-core divestment was delayed again.
What's new
- FY26 revenue of ₹1,159 cr missed internal targets.
- Q4 saw ₹142 cr in revenue deferred due to supply chain constraints.
- The heavy engineering business divestment is delayed until H1 FY27.
- Three manufacturing facilities are coming online through FY27.
Themes from the call
Demand
Revenue recognition of ₹142 cr moved to FY27 as suppliers redirected materials to war-related programs.
Margins
EBITDA margins reached 15.3% after a 150 bps expansion from the prior year.
Capital allocation
The company allocated ₹1,600 cr for facility capex and ₹600 cr for acquisitions, planning to fund this via divestments and internal accruals.
Guidance watch
- Targets FY27 revenue of ₹1,377 cr.
- Maintains a ₹9,000 cr revenue target by FY30.
Risk flags
- Divestment delays create uncertainty for balance sheet liquidity.
- Converting design wins to manufacturing lacks a proven track record at scale.
Key quotes
-
"When we move to manufacturing, it is automatically a 10-times or 20-times increase. We are not scaling down the target; we are sticking to 9,000 crores."
— Dr. Sampath Ravinarayan, CEO -
"Second, phase two of our divestment, which is central to our restructuring plan, has delayed a bit. It remains a priority for H1 FY27."
— Dr. Sampath Ravinarayan, CEO
The brief
Axiscades faces a credibility gap. For three quarters, management insisted on 45% EBITDA growth and a March 2026 deadline for shedding non-core assets. Neither occurred. The company delivered 24.6% EBITDA growth and pushed the divestment timeline into H1 FY27.
Dr. Sampath Ravinarayan claims converting design wins into manufacturing output provides a 10-20x value increase. This assumption justifies the ₹9,000 cr FY30 revenue target. To meet this, the company began a multi-year capex cycle with facilities in Hyderabad and Devanahalli.
The Q4 performance shows operational strain. Supply chain shifts forced the deferral of ₹142 cr in revenue, a sign that program management failed to handle material redirection. Management calls this a timing issue. Regardless, the reliance on future manufacturing conversion adds risk to the upcoming quarters.
The company plans to spend ₹1,600 cr on facilities and ₹600 cr on acquisitions. These depend on divestment proceeds and internal cash flows. If the divestment stalls again, the company faces a liquidity squeeze. Axiscades is betting its future on a manufacturing pivot. Investors should wait for the company to meet a short-term target before trusting the long-term goal.
Axiscades is betting on a manufacturing pivot, but it needs to stop missing its own growth targets first.